Send to

Choose Destination
Kidney Int. 2018 Oct;94(4):663-673. doi: 10.1016/j.kint.2018.06.011.

Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management.

Author information

Department of Nephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. Electronic address:
Department of Gastroenterology, Hepatology Unit & Instituto de Investigación La Fe, Hospital Universitari i Politècnic La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Valencia, Spain; School of Medicine, University of Valencia, Valencia, Spain.
National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
Division of Nephrology, Maggiore Hospital and IRCCS Foundation, Milano, Italy.
Department of Virology, Hepatitis E Virus National Reference Centre, Toulouse University Hospital, Toulouse, France; Toulouse-Purpan Centre for Pathophysiology, INSERM UMR1043/CNRS UMR 5282, CPTP, Toulouse University Paul Sabatier, Toulouse, France.
George Institute for Global Health, New Delhi, India; University of Oxford, Oxford, UK.
Departments of Nephrology and Organ Transplantation, CHU Rangueil; INSERM U1043, IFR-BMT, CHU Purpan; Université Paul Sabatier, Toulouse, France.
Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA; Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, Minnesota, USA.
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China; State Key Lab for Liver Research, The University of Hong Kong, Hong Kong, China.
Nephrology Department, Research Institute, Hospital 12 Octubre, Madrid, Spain.
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Hepatology Department, Hopital Cochin, Université Paris Descartes, INSERM U-1223, Institut Pasteur, Paris, France.
Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina; Latin American Liver Research, Educational and Awareness Network (LALREAN), Pilar, Provincia de Buenos Aires, Buenos Aires, Argentina.
Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island, USA.
Renal Section, Boston University Medical Center, Boston, Massachusetts, USA.
Evidera, Waltham, Massachusetts, USA.
Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island, USA; Rhode Island Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Division of Hepatology, University of Miami, Miami, Florida, USA. Electronic address:


Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.


KDIGO; antivirals; chronic kidney disease; cryoglobulinemia; dialysis; direct-acting antivirals; glomerular diseases; guideline; hemodialysis; hepatitis C virus; infection control; kidney transplantation; liver testing; nosocomial transmission; screening; systematic review

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center